Spero Therapeutics Analyst Ratings
Spero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 400% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 08/01/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/20/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/10/2023 | 328.57% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 09/26/2022 | 328.57% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 09/23/2022 | 471.43% | Evercore ISI Group | $2 → $8 | Upgrades | In-Line → Outperform |
| 08/15/2022 | 400% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
| 05/23/2022 | 614.29% | HC Wainwright & Co. | $37 → $10 | Maintains | Buy |
| 05/20/2022 | 42.86% | Berenberg | → $2 | Downgrades | Buy → Hold |
| 05/17/2022 | 257.14% | Cantor Fitzgerald | $27 → $5 | Maintains | Overweight |
| 05/04/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 05/04/2022 | 42.86% | Evercore ISI Group | $40 → $2 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 2542.86% | HC Wainwright & Co. | $43 → $37 | Maintains | Buy |
| 03/21/2022 | 2971.43% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/22/2021 | 2757.14% | HC Wainwright & Co. | $33 → $40 | Maintains | Buy |
| 12/16/2020 | 3257.14% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 11/23/2020 | 2257.14% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 09/29/2020 | 4900% | Evercore ISI Group | → $70 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1900% | HC Wainwright & Co. | $25 → $28 | Reiterates | → Buy |
| 03/17/2020 | 1400% | Stifel | $22 → $21 | Maintains | Buy |
| 11/05/2019 | 2400% | HC Wainwright & Co. | $28 → $35 | Maintains | Buy |
| 09/09/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 09/04/2019 | 1900% | HC Wainwright & Co. | → $28 | Assumes | → Buy |
| 10/16/2018 | 542.86% | B of A Securities | $19 → $9 | Downgrades | Neutral → Underperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 400% | HC Wainwright公司 | $6→$7 | 維護 | 買 |
| 08/01/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 07/20/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 04/10/2023 | 328.57% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 09/26/2022 | 328.57% | HC Wainwright公司 | $7→$6 | 維護 | 買 |
| 09/23/2022 | 471.43% | Evercore ISI集團 | $2→$8 | 升級 | 線內→表現優異 |
| 2022年08月15日 | 400% | HC Wainwright公司 | $10→$7 | 維護 | 買 |
| 2022年05月23日 | 614.29% | HC Wainwright公司 | $37→$10 | 維護 | 買 |
| 05/20/2022 | 42.86% | 貝倫伯格 | →$2 | 評級下調 | 購買→Hold |
| 2022/05/17 | 257.14% | 康託·菲茨傑拉德 | $27→$5 | 維護 | 超重 |
| 05/04/2022 | - | 考恩公司 | 評級下調 | 跑贏→市場表現 | |
| 05/04/2022 | 42.86% | Evercore ISI集團 | $40→$2 | 評級下調 | 勝過→同線 |
| 04/18/2022 | 2542.86% | HC Wainwright公司 | $43→$37 | 維護 | 買 |
| 03/21/2022 | 2971.43% | HC Wainwright公司 | $40→$43 | 維護 | 買 |
| 10/01/2021 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 2021/01/22 | 2757.14% | HC Wainwright公司 | $33→$40 | 維護 | 買 |
| 12/16/2020 | 3257.14% | 貝倫伯格 | →$47 | 開始承保 | →購買 |
| 11/23/2020 | 2257.14% | HC Wainwright公司 | $28→$33 | 維護 | 買 |
| 09/29/2020 | 4900% | Evercore ISI集團 | →$70 | 開始承保 | →跑贏大盤 |
| 05/11/2020 | 1900% | HC Wainwright公司 | $25→$28 | 重申 | →購買 |
| 03/17/2020 | 1400% | Stifel | $22→$21 | 維護 | 買 |
| 2019年11月05日 | 2400% | HC Wainwright公司 | $28→$35 | 維護 | 買 |
| 2019年09月09日 | - | 詹尼·蒙哥馬利·斯科特 | 開始承保 | →購買 | |
| 2019年09月04日 | 1900% | HC Wainwright公司 | →$28 | 假設 | →購買 |
| 2018年10月16日 | 542.86% | B of A證券 | $19→$9 | 評級下調 | 中性→表現不佳 |
What is the target price for Spero Therapeutics (SPRO)?
Spero治療公司(SPRO)的目標價格是多少？
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 400.00% upside). 7 analyst firms have reported ratings in the last year.
2023年8月14日，HC Wainwright&Co.報道了Spero治療公司(納斯達克代碼：SPRO)的最新目標價。這家分析公司將目標價定為7美元，預計SPRO將在12個月內升至(可能上漲400.00%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
Spero治療公司(SPRO)的最新分析師評級是多少？
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics maintained their buy rating.
對斯佩羅治療公司(納斯達克代碼：SPO)的最新分析師評級由HC Wainwright&Co.提供，斯佩羅治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Spero治療公司(SPRO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Spero治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Spero治療公司的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候提供。
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
分析師對Spero Treeutics(SPRO)的評級正確嗎？
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a maintained with a price target of $6.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.40, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Spero治療公司(SPRO)評級保持不變，目標價在6.00美元至7.00美元之間。Spero治療公司(SPRO)目前的交易價格為1.40美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。